1 Boyer EW, Shannon M. The Serotonin-Syndrome. N Engl J Med. 2005;352:1112–20.
2 Foong AL, Grindrod KA, Patel T, Kellar J. Demystifying Serotonin-Syndrome (or serotonin toxicity). Can Fam Physician. 2018;64:720–7.
3 Bertoli R, Tosi M, Vanini G, Caduff P, Cerny A. Sertonin-Syndrom bei Mirtazapin-Monotherapie. Swiss Med Forum. 2005;34(5):859–61.
4 Stephan P, Ramseier F, Etzensberger M, E. JS. Klonus, Hyperreflexie und Agitation bei einer Patientin mit hohem Fluvoxamin-Serumspiegel: Symptome der Serotonin-Toxizität. Swiss Med Forum. 2008;6(8):100–3.
5 Rickli A, Liakoni E, Hoener MC, Liechti ME. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of Serotonin-Syndrome. Br J Pharmacol. 2018;175:532–43.
6 Asch DA, Parker RM. The Libby Zion case. One step forward or two steps backward? N Engl J Med. 1988;318:771–5.
7 Orlova Y, Rizzoli P, Loder E. Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin-Syndrome. JAMA Neurol. 2018;75:566–72.
8 Krahenbuhl S, Raisin J, Herren T. [Malignant neuroleptic syndrome under metoclopramide and neuroleptics in anuria]. Schweiz Med Wochenschr. 1993;123:1359–62.
9 Wu CS, Tong SH, Ong CT, Sung SF. Serotonin-Syndrome Induced by Combined Use of Mirtazapine and Olanzapine Complicated with Rhabdomyolysis, Acute Renal Failure, and Acute Pulmonary Edema – A Case Report. Acta Neurol Taiwan. 2015;24:117–21.